艾司奥美拉唑和兰索拉唑联合阿莫西林治疗胃溃疡的临床效果对比  

Comparison of clinical effects of esomeprazole and lansoprazole combined with amoxicillin in the treatment of gastric ulcer

作　　者：陈相君 CHEN Xiang-jun(Department of Internal Medicine,Hospital of Tai’an Tourism Economic Development Zone,Tai’an 271000,China)

机构地区：[1]泰安市旅游经济开发区医院内科,271000

出　　处：《中国实用医药》2021年第34期33-36,共4页China Practical Medicine

摘　　要：目的对比胃溃疡(GU)患者分别应用艾司奥美拉唑和兰索拉唑与阿莫西林联合治疗的临床疗效。方法72例GU患者,根据治疗方案不同分为对照组及研究组,每组36例。对照组采用兰索拉唑+阿莫西林治疗,研究组采用艾司奥美拉唑+阿莫西林治疗。比较两组临床疗效、不良反应发生情况、炎性指标水平以及治疗前后临床症状积分。结果研究组总有效率为97.22%(35/36),明显高于对照组的77.78%(28/36),差异有统计学意义(P<0.05)。治疗后,研究组乏力、反酸、烧灼感及上腹部疼痛积分分别为(0.81±0.12)、(0.75±0.09)、(0.82±0.21)、(0.79±0.15)分,低于对照组的(1.56±0.21)、(1.62±0.11)、(1.54±0.11)、(1.49±0.08)分,差异有统计学意义(P<0.05)。治疗后,研究组超敏C反应蛋白(hs-CRP)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)水平分别为(3.75±0.25)mg/L、(8.62±1.05)ng/L、(13.98±1.02)ng/L,低于对照组的(6.27±1.23)mg/L、(11.72±2.35)ng/L、(17.49±1.47)ng/L,差异有统计学意义(P<0.05)。研究组不良反应发生率为5.56%(2/36),明显低于对照组的22.22%(8/36),差异有统计学意义(P<0.05)。结论临床给予GU患者艾司奥美拉唑+阿莫西林治疗可显著改善其症状及临床疗效,缓解炎性反应,减少不良反应,临床用药安全性较高。Objective To compare the clinical efficacy of esomeprazole and lansoprazole combined with amoxicillin in the treatment of gastric ulcer(GU).Methods A total of 72 patients with GU were divided into control group and research group according to different treatment regimens,with 36 cases in each group.The control group was treated with lansoprazole and amoxicillin,and the research group was treated with esomeprazole and amoxicillin.The clinical efficacy,occurrence of adverse reactions,inflammatory index levels,and the clinical symptom scores before and after treatment were compared between the two groups.Results The total effective rate in the research group was 97.22%(35/36),which was significantly higher than 77.78%(28/36)in the control group,and the difference was statistically significant(P<0.05).After treatment,the scores of fatigue,acid reflux,burning sensation and upper abdominal pain in the research group were(0.81±0.12),(0.75±0.09),(0.82±0.21),(0.79±0.15)points,respectively,which were lower than(1.56±0.21),(1.62±0.11),(1.54±0.11),(1.49±0.08)points in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of high-sensitivity C-reactive protein(hs-CRP),interleukin-8(IL-8),and tumor necrosis factor-α(TNF-α)in the research group were(3.75±0.25)mg/L,(8.62±1.05)ng/L,(13.98±1.02)ng/L,which were lower than(6.27±1.23)mg/L,(11.72±2.35)ng/L,(17.49±1.47)ng/L in the control group,and the difference was statistical significance(P<0.05).The incidence of adverse reactions in the research group was 5.56%(2/36),which was significantly lower than 22.22%(8/36)in the control group,and the difference was statistically significant(P<0.05).Conclusion Clinical treatment with esomeprazole and amoxicillin for GU patients can significantly improve their symptoms and clinical efficacy,relieve inflammatory reactions,reduce adverse reactions,and have high clinical safety.

关 键 词：胃溃疡 阿莫西林 艾司奥美拉唑 兰索拉唑 临床疗效 炎性水平 

分 类 号：R573.1[医药卫生—消化系统]